Biocon Ltd

Biocon Ltd

Biocon Ltd held its 48th Annual General Meeting (AGM) on August 06, 2026, through video conferencing, with 90 members present. The meeting was attended by the company's directors, key managerial personnel, and statutory auditors. The Chairperson, Ms. Kiran Mazumdar-Shaw, welcomed the attendees and informed about the non-attendance of certain directors due to personal exigencies. The meeting concluded with the appreciation of outgoing directors and auditors.

Biocon Ltd

Biocon Ltd has announced the availability of the audio and video recording of its Q1 FY27 earnings call, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Biocon Ltd

Biocon Ltd has announced its Q1 FY27 earnings, with revenue from operations at ₹4,336 Cr, a 10% YoY growth. The company's biosimilars segment saw a 16% YoY growth, driven by the North America market, while the generics segment reported a 21% YoY growth. The company's EBITDA margin for the biosimilars segment was 25%, and 7% for the generics segment.

Biocon Ltd

Biocon Ltd has received a Monitoring Agency Report from India Ratings & Research Private Limited for the quarter ended June 30, 2026, regarding the utilization of proceeds raised through Qualified Institutions Placement. The report states that there is no deviation from the objects of the issue.

Biocon Ltd

Biocon Ltd announced its consolidated financial results for Q1FY27, with total income at Rs 4,391 Cr, up 9% YoY, driven by strong growth in the Biopharma business. Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets.

Biocon Ltd

Biocon Ltd announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 638 million and a basic earnings per share of Rs. 0.32. The company's consolidated financial results also showed a net profit of Rs. 1,368 million. The results will be available on the company's website.

Biocon Ltd

Biocon Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, showing a net profit of Rs. 522 million. The company's revenue from operations was Rs. 6,245 million, and its expenses were Rs. 6,194 million. The results are available on the company's website.

Biocon Ltd

Biocon Ltd has announced the commercial launch of Yesafili, a biosimilar to Eylea 2 mg, in the United States. The product is a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions.

Biocon Ltd

Biocon Ltd has commercially launched Yesafili, a biosimilar Aflibercept, in the United States, expanding its global presence in ophthalmology and increasing access to life-changing medicines for patients with eye conditions.

Biocon Ltd

Biocon Ltd receives Health Canada approval for Yesintek (ustekinumab) Autoinjector Pen, expanding its portfolio of immunology products in Canada.

Biocon Ltd

Biocon Ltd has announced an earnings conference call for analysts and investors to discuss Q1 FY 2026-27 financial results, scheduled for August 6, 2026.

Biocon Ltd

Biocon Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 to consider and approve Intimation for the Board Meeting and Earnings Conference Call for Analysts and Investors.

Biocon Ltd

Biocon Ltd informs that Mr. Bobby Kanubhai Parikh has completed his second term as an Independent Director and ceased to be a Director of the Company w.e.f. July 22, 2026. The Board appreciates his contributions and gratitude.

Biocon Ltd

Biocon Limited announced that its partner, Duopharma Biotech Berhad, secured multiple insulin contracts valued over MYR 225 million from the Ministry of Health, Malaysia. Biocon's Malaysian subsidiary, Biocon Sdn. Bhd., will supply various insulin products including recombinant human insulin, insulin glargine, and insulin aspart under these contracts, which include a three-year agreement for human insulin (~MYR 155.27 million) and two 2-year agreements for insulin glargine (~MYR 18 million) and insulin aspart (~MYR 52.5 million). This reinforces Biocon's long-standing commitment and presence in Malaysia's diabetes care market.

Biocon Ltd

Biocon Ltd has issued a communication to its shareholders regarding the deduction of Tax at Source (TDS) on the final dividend recommended for the Financial Year 2025-26. The Board had recommended a final dividend of Re. 0.50 per equity share, which is subject to shareholder approval at the upcoming Annual General Meeting on August 06, 2026, with a record date of July 03, 2026. The company details the varying TDS rates based on shareholder categories and residential status and advises shareholders to update their details for accurate tax processing.